CD7 CAR-T therapy for relapsed T-cell leukemia/lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has returned or not responded to at least two standard treatments.
- Your cancer cells have the CD7 protein, confirmed by a recent biopsy or blood test.
- You are between 18 and 75 years old.
- You are in generally good health with adequate heart, liver, and kidney function.
- You are not pregnant, breastfeeding, or planning to become pregnant within 2 years of treatment.
- You have not had CAR-T therapy or other gene-modified cell therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called CD7 CAR-T for children with high-risk T-cell lymphoblastic leukemia or lymphoma who have finished initial chemotherapy and are in remission. It aims to prevent relapse.
This trial tests a new immune cell therapy (CD7 CAR-T) given as a bridge to a stem cell transplant in people with relapsed or hard-to-treat CD7-positive leukemia. The goal is to help control the leukemia and improve chances for a successful transplant.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
This trial tests a new treatment made from your own immune cells, designed to target and kill cancer cells that have a protein called CD7. It might help people with T-cell leukemia or lymphoma that has returned or not responded to standard treatments.
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
Hear when a new T Lymphoblastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.